Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

benzinga.com/general/biotech/25/05/45648350/why-is-gsk-partner-spero-therapeutics-stock-skyrocketing-on-wednesday

GSK plc (NYSE:GSK) and Spero Therapeutics Inc (NASDAQ:SPRO) on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.
Spero’s stock price was up 245.89% at last check Wednesday…

This story appeared on benzinga.com, 2025-05-28 15:24:21.
The Entire Business World on a Single Page. Free to Use →